STOCK TITAN

Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) will participate in the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. The President, CEO, and CFO will engage in a Q&A session, providing insights into the company's mission-critical automation solutions for healthcare product manufacturing.
Positive
  • None.
Negative
  • None.

LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a question-and-answer session with the host analyst on Tuesday, March 19, 2024, at 12:00 p.m. Eastern Time. This presentation time has been updated from the Company’s previously announced schedule.

A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcasts will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.


FAQ

When will Rapid Micro Biosystems participate in the KeyBanc Life Sciences & MedTech Investor Forum?

Rapid Micro Biosystems will participate in the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024.

Who are the key executives from Rapid Micro Biosystems participating in the event?

The President and CEO, Rob Spignesi, and the CFO, Sean Wirtjes, will engage in a question-and-answer session at the event.

Where can investors access the live webcast of the presentation?

Investors can access the live webcast of the presentation on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/.

Will the webcast be available for replay after the event?

Yes, the webcasts will be archived and available for replay after the event.

What is Rapid Micro Biosystems' ticker symbol?

Rapid Micro Biosystems' ticker symbol is RPID.

Rapid Micro Biosystems, Inc.

NASDAQ:RPID

RPID Rankings

RPID Latest News

RPID Stock Data

35.20M
9.13M
12.26%
64.97%
0.14%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
LOWELL

About RPID

rapid micro biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. the company's growth direct(tm) system detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. the growth direct(tm) system is the first and only automated system that accelerates testing while fitting with current regulatory practices and addressing all key applications.